NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lakefront Biotherapeutics NV (LKFT) Stock Analysis

Lakefront Biotherapeutics NV (LKFT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LKFT

$30.58

−$0.17 (−0.55%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LKFT with… →

LKFT Key Statistics

As of Oct 21, 2026
Trading
Open
$30.75
Previous Close
$30.75
Day's Range
30.39–30.85
52-Week Range
25.68–36.24
Volume
134.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.06
Valuation
Market Cap
$2.00B
P/E Ratio
2.91
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.02
EPS (ttm)Profit attributable to each share over the last twelve months.
10.52
Financials (FY)
Revenue (FY)
$1.11B+303.50%
Net Income (FY)
$320.88M+333.15%
Profit marginThe share of revenue left as profit after all costs and taxes.
60.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.48M
1-Year Return
−2.70%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
277.48K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LKFT closed at $30.58, −2.70% over 1 year.

Lakefront Biotherapeutics NV (LKFT) has a market capitalization of $2.00B.

In fiscal 2025, LKFT reported revenue of $1.11B.

LKFT Stock Return by Calendar Year

Lakefront Biotherapeutics NV (LKFT) 10-year return: what $10,000 became

1 year
$10,000 $9,730
−2.70%
5 years
$10,000 $5,888
−41.12%
10 years
$10,000 $4,652
−53.48%

If you had invested $10,000 in Lakefront Biotherapeutics NV (LKFT) 10 years ago, at the close on October 21, 2016, it would have been worth $4,652 at the close on October 21, 2026: −53.48% in total, −7.37% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.48%
2025+18.91%
2024−32.35%
2023−8.40%
2022−19.50%
2021−44.30%
2020−52.14%
2019+125.45%
2018−2.15%
2017+46.07%
2016 (partial year)+19.09%

As of October 21, 2026.

LKFT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.11B$320.88M28.9%
2024$275.65M$74.08M26.9%
2023$239.72M$211.70M88.3%
2022$241.25M−$217.99M−90.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.11B$1.08B$501.39M$320.88M28.9%
2024$275.65M$240.79M−$188.34M$74.08M26.9%
2023$239.72M$239.72M−$88.26M$211.70M88.3%
2022$241.25M$241.25M−$131.06M−$217.99M−90.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LKFT Valuation vs Biotechnology Median

Median of 608 stocks
MetricLKFTBiotechnology medianvs median
P/E2.9116.600.2x the median
P/S ratio2.0213.300.2x the median
Profit margin60.23%−38.31%98.5 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lakefront Biotherapeutics NV (LKFT) is capitalised at $2.00B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 196 employees.

The 52-week range on file runs from $25.68 to $36.24. LKFT last closed at $30.58 on October 21, 2026. That is −$0.17 (−0.55%) against the previous close. The latest close sits 19.08% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.11B. Against the prior fiscal year total of $275.65M, that is a change of +303.50%. The same year closed with net income of $320.88M. That is +333.15% against the prior fiscal year. Profit margin runs at 60.23%. That is 98.5 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 10.52.

Across the 4 fiscal years on file, revenue moves from $241.25M in 2022 to $1.11B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

LKFT trades at a trailing price-to-earnings ratio of 2.91. That is 0.2 times the Biotechnology median of 16.6. The price-to-sales ratio is 2.02. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −2.70%. Measured over 10 years, that is −7.37% a year compounded. The reported beta is 0.06. Daily returns over the trailing 10 years annualize to a volatility of 37.85%.

Growth & Income

No dividend is on file for LKFT.

The strongest complete calendar year on file is 2019 at +125.45%; the weakest is 2020 at −52.14%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −6.48% year to date.

Peer Comparison

Lakefront Biotherapeutics NV (LKFT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lakefront Biotherapeutics NV LKFT $2.00B 2.9
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lakefront Biotherapeutics NV trades at a P/E of 2.9.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Visit website →